2024-09-11 05:59:20
Emmanuel Macron, during the inauguration of the Sanofi factory in Neuville-sur-Saône (Rhône), Tuesday September 10, 2024. LAURENT CIPRIANI / AFP
Mini-factories on wheels. In the production area of the new Sanofi factory, located on the banks of the Saône, in Neuville-sur-Saône (Rhône), in the Lyon region, almost everything is mobile and modular. Including the vast dark blue inflatable partition that, at the time of our visit, separates the place into two distinct spaces. “If necessary, it can be dismantled in an hour.”explains Thomas Triomphe, head of vaccines at Sanofi.
Read also | Article reserved for our subscribers The sale of Doliprane creates friction between Sanofi and Bercy
Add to your selections
The only fixed elements are the large metal panels on the walls, these “docking stations” which, connected to the various mobile equipment, will transport the raw materials necessary for the manufacture of vaccines and supply the machines with electricity, water, or oxygen. “In fact, we have to imagine this factory as a Lego game, where we adapt the elements used according to the manufacturing processes specific to each product. For example, a vaccine may require equipment A, B, C, while another will require equipment X, Y, Z.”explains Mr. Triomphe.
This flexibility, welcomed by Emmanuel Macron, who came to inaugurate the new 24,000 square meter building on Tuesday, September 10, is the whole point. “Four years ago, we were in the middle of Covid. We realized what the loss of sovereignty cost. (…) We thought we needed to be able to adapt to innovations much faster. », stressed the President of the Republic. The plant will thus make it possible to simultaneously produce up to four vaccines or biomedicines, regardless of the technologies used, whether they are live attenuated viral vaccines, recombinant protein, messenger RNA, or treatments derived from biotechnologies such as enzymes or monoclonal antibodies.
Read also | Article reserved for our subscribers Sanofi is strengthening its research to play in the big leagues
Add to your selections
“More modern, ecological and connected”
Table of Contents
Table of Contents
By opting for this modular concept, Sanofi is breaking the codes of the pharmaceutical industry. Because, traditionally, an industrial site for vaccines or biomedicines, once built, is only designed for the production of the same product or technology. Changing its use to integrate the manufacture of another drug, due to the complexity of the production processes, costs and authorizations required from health authorities, is often such a challenge that manufacturers prefer to opt for the construction of a new building from scratch.
Read also | Article reserved for our subscribers Sanofi invests 1.1 billion euros for the construction of a new factory in France
Add to your selections
Conversely, the Neuville-sur-Saône plant will be able to switch from one product or technology to another in a matter of days or weeks. In the event of a shortage or pandemic, the site will thus be able to respond more quickly to health emergencies and massively increase its production capacity by reconfiguring the space. The site will be able to produce up to 500 million doses of vaccines per year. “This is not just a new, more modern, ecological and connected factory, but a revolution in the way we will manufacture vaccines and biomedicines in the coming decades.”underlines Paul Hudson, CEO of Sanofi.
You have 14.14% of this article left to read. The rest is reserved for subscribers.
1726036522
#Sanofi #bets #revolutionary #factory #respond #future #pandemics
Emmanuel Macron and Sanofi: A Commitment to Vaccine Sovereignty and Innovation
On September 10, 2024, French President Emmanuel Macron inaugurated a new Sanofi factory in Neuville-sur-Saône, Rhône, marking a significant milestone in the country’s pursuit of vaccine sovereignty and innovation. This event is a testament to the strong partnership between Macron and Sanofi, which has been instrumental in shaping France’s response to the COVID-19 pandemic.
A Brief History of Macron and Sanofi’s Partnership
In May 2020, Macron summoned Sanofi’s CEO, Paul Hudson, to discuss the company’s decision to prioritize the United States in its vaccine development and distribution plans. Hudson had stated that the US government had “the right to the largest pre-order of vaccines]because it’s invested in taking the risk”[[1[[1[[1[[1[[1[[1[[1[[1]. Macron’s meeting with Hudson was a signal that France would not shy away from asserting its interests in the vaccine market.
The Neuville-sur-Saône Factory: A Symbol of Innovation and Flexibility
The new Sanofi factory in Neuville-sur-Saône is a 24,000 square meter facility designed to produce up to four vaccines or biomedicines simultaneously, regardless of the technologies used. This modular concept breaks away from traditional pharmaceutical industry norms, where industrial sites are typically designed for the production of a single product or technology. The factory’s flexibility allows for rapid adaptation to new innovations and technologies, enabling Sanofi to respond swiftly to emerging health crises.
Macron’s Vision for Vaccine Sovereignty
During the inauguration ceremony, Macron emphasized the importance of vaccine sovereignty, highlighting the lessons learned from the COVID-19 pandemic. “Four years ago, we were in the middle of Covid. We realized what the loss of sovereignty cost. We thought we needed to be able to adapt to innovations much faster,” he stated. Macron’s vision is to ensure that France has the capacity to develop and produce vaccines independently, reducing its reliance on external suppliers.
Sanofi’s Commitment to Research and Development
Sanofi has invested heavily in research and development, with a focus on strengthening its position in the global vaccine market. The company’s commitment to innovation is reflected in its investment of 1.1 billion euros in the construction of a new factory in France [3[3[3[3[3[3[3[3].
Conclusion
The partnership between Emmanuel Macron and Sanofi is a testament to France’s commitment to vaccine sovereignty and innovation. The Neuville-sur-Saône factory is a symbol of this partnership, demonstrating Sanofi’s willingness to break away from traditional industry norms and adapt to emerging health crises. As Macron stated, “We thought we needed to be able to adapt to innovations much faster.” The future of vaccine development and production in France looks promising, with Macron and Sanofi leading the way.
Sanofi’s Innovative Factory: A Game-Changer in the Pharmaceutical Industry
On September 10, 2024, French President Emmanuel Macron inaugurated Sanofi’s state-of-the-art factory in Neuville-sur-Saône, Rhône. This cutting-edge facility is poised to revolutionize the pharmaceutical industry with its modular and flexible design, enabling the production of up to four vaccines or biomedicines simultaneously, regardless of the technology used.
Modular Concept: The Future of Pharmaceutical Manufacturing
Sanofi’s innovative approach to manufacturing is centered around a modular concept, where almost everything is mobile and modular. The factory’s production area features large metal panels on the walls, known as “docking stations,” which connect to various mobile equipment to transport raw materials and supply machines with electricity, water, or oxygen [[1]]. This design allows for quick adaptation to different manufacturing processes, making it possible to switch from one product to another in a relatively short period.
Flexibility and Adaptability
The Neuville-sur-Saône plant’s flexibility is a significant departure from traditional pharmaceutical manufacturing sites, which are typically designed for the production of a single product or technology. Sanofi’s modular approach enables the factory to adapt quickly to innovations and changes in the industry, reducing the need for costly and time-consuming construction of new buildings [[2]].
Embracing Sustainability and Connectivity
Sanofi’s commitment to sustainability and connectivity is evident in the design of the Neuville-sur-Saône factory. The facility is designed to be more modern, ecological, and connected, with a focus on reducing environmental impact and promoting collaboration and innovation.
Sanofi’s Rich History and Commitment to Research
Sanofi is a global leader in the pharmaceutical industry, with a rich history of innovation and commitment to research and development [[3]]. The company operates 16 production sites, 4 research and development sites, and 5 tertiary sites across France, making it a key player in the country’s pharmaceutical sector.
A New Era in Pharmaceutical Manufacturing
Sanofi’s Neuville-sur-Saône factory marks a new era in pharmaceutical manufacturing, with its modular and flexible design, commitment to sustainability, and focus on innovation and connectivity. As the industry continues to evolve, Sanofi’s forward-thinking approach is poised to shape the future of pharmaceutical production and research.
References:
[[1]]Sanofi France. (n.d.). Le site de production de Sanofi Marcy-L’Étoile. Retrieved from
[[2]]Sanofi France. (n.d.). Nos sites en France. Retrieved from
[[3]]Sanofi France. (n.d.). Le site de production de Lyon Gerland. Retrieved from
